A stenosis occurring at, or adjacent to, a significant division of a major epicardial coronary artery: Bifurcation lesions account for 1–20% of all percutaneous coronary interventions (PCIs), and treatment remains technically challenging despite advances in PCI techniques and third-generation drug-eluting stent (DES) technology. In general, outcomes are less favourable, with an increase in the rates of major adverse cardiac events (MACE), target lesion revascularisation (TLR) and target vessel revascularisation.

Recommendations from the European Bifurcation Club (EBC) derived from a systematic evaluation of over 10 years of data comparing a provisional single stent (main vessel [MV] only) with a planned two stent (MV plus side branch [SB]) conclude that a provisional single-stent approach should be the technique of choice for the treatment of the majority of bifurcation lesions. If SB coverage is then required, either a T or T and protrude (TAP) technique can be adopted to secure the carina itself is subject to high shear stress and flow, and hence often free from significant atheroma. Systematic histopathological analysis has confirmed this, questioning the benefit of covering this area with metallic stent layers overlapping. Compounding this is the inherent geometric disparity between the Y-shape of the bifurcation and the cylindrical tube of an expanded stent. This can delay healing, with reduced intima formation over these sites, which may explain the higher incidence of procedural myocardial infarction (MI), stent thrombosis and restenosis that has been observed with such techniques.7 The use of the AXXESS stent in the treatment of complex bifurcation lesions.

To be certain of ostial coverage, all two-stent bifurcation techniques (crush/TAP/culotte etc) result in neocarina formation, with multiple metallic stent layers overlapping. One solution to these issues is the dedicated AXXESS™ bifurcation stent system (Biosensors Interventional Technologies, Singapore). This follows a provisional strategy while offering predictable access to the SB and MV in the long term, with the absence of metallic layers at the carina. The aim of this article is to describe the indication, implantation technique and outcome data supporting the use of the AXXESS stent in the treatment of coronary bifurcation lesions.

The successful treatment of coronary bifurcation lesions remains one of the challenges of interventional cardiology. The current consensus of the European Bifurcation Club based on published data advocates a provisional strategy, treating the main vessel (MV) with a single stent covering the side branch (SB), with bailout SB stenting as required. The success of this approach may be limited by failure to attain SB access after MV stenting but is preferred in most situations over routine SB plus MV stent techniques, which are associated with a significant increase in the rate of major adverse cardiac events. The AXXESS self-expanding biolimus-eluting stent has been developed as a solution to these challenges within the coronary circulation and maintains provisional MV stent approach but with added assurance of maintained SB access. It has a unique conical structure that is positioned spanning the carina, with scaffold extending into the carina of both the MV and SB. The purpose of this article is to describe the indication, implantation technique and outcome data supporting the use of the AXXESS stent in the treatment of coronary bifurcation lesions.

**Keywords**

AXXESS stent, bifurcation, self-expanding, biolimus, provisional
The AXXESS system is conventionally 7 French (7 Fr) compatible, although can be delivered through a specific 6 Fr guide catheter with an internal lumen diameter of 0.072" (e.g. the Adroit guide, Cordis Miami, Florida, USA; but only with a single guide wire). It is delivered through a hydrophilic-coated rapid-exchange system comprising a delivery catheter, mounted stent and cover sheath (Figure 2). The stent is delivered following gradual withdrawal of this sheath, with the technique for implantation being described in detail below. One radiopaque gold marker exists at the proximal edge, with three at the distal edge arranged at equal intervals on the circumference to visually guide optimal placement (Figure 2). It is positioned spanning the carina into the ostium of both the MV and the SB.

**Indications for Implantation**

Any Medina classification of bifurcation can be treated using the AXXESS system. However, the angle between the MV and SB should not be greater than 70° and, ideally, the SB should be a minimum of 2.5 mm in diameter and have minimal calcification. In order to clearly define the bifurcation angle, two orthogonal radiographic projections are often required. As it elutes Biolimus A9, the standard contraindications for drug-eluting devices apply. There are no restrictions in location, with devices being used successfully throughout the coronary circulation, including the left main bifurcation; however, it cannot be overexpanded and careful vessel sizing (often requiring intravascular imaging) should be performed. It can be implanted for the full range of coronary interventional indications, including acute coronary syndromes and stable angina.

AXXESS is particularly useful in the treatment of Medina class 1,0,0 lesions, as it is often the only device required in these cases. When treating all other Medina classes, additional distal overlapping DES in either MV or SB may be required.

**Technique of Implanting an AXXESS™ Stent**

Although the AXXESS device can be delivered through any 7 Fr guiding system, when considering guide shape, support should be maximised to facilitate device delivery. Two separate guide wires (any moderate support 0.014" wire) should be advanced distally into the MV and SB. The use of dedicated stents, particularly self-expanding devices, require thorough lesion preparation, particularly in more complex calcified lesions (e.g. Medina 1,1,1). Consequently, noncompliant balloons, cutting balloons and adjunctive devices such as rotational atherectomy should be considered early to optimise final position, minimal luminal area and stent expansion. Passage of a ‘winged’ cutting balloon distal to the target lesion is an indicator that the AXXESS device can be delivered into the appropriate position. Predilatation is therefore strongly recommended before delivering the AXXESS stent, with vessel preparation of both MV and, in the majority of cases, into the ostium of the SB if disease is present.

The AXXESS™ stent is advanced onto the wire of the distal vessel with the sharpest bend to the proximal MV. This can be either branch, but in a series of over 100 implanted devices evaluated by our group it was positioned on the MV wire in 92 % of cases. The distal markers of the AXXESS stent are advanced beyond the carina in the distal vessel. The whole device is then gently retracted, alongside simultaneous gradual pullback of the actuator, slowly retracting the sheath. This allows progressive flaring of the three distal markers across the carina. Angiographically, this is visualised when one marker appears to be in either MV or SB, with the other two markers positioned in the other vessel, spanning the carina. While the cover

---

**Bifurcations**

**The AXXESS Stent**

The Biosensors AXXESS Biolimus A9™ eluting coronary bifurcation stent system is a conically shaped self-expanding DES, constructed from a nickel-titanium alloy (nitiol). The stent is designed to dynamically adapt to the Y shape of the carina up to an angle of 70°, maintaining native geometry without metallic struts, and facilitating long-term SB access (Figure 2).

The stent has an abluminal polymer coating composed of polylactic acid, that is biodegradable into carbon dioxide and water within 6–9 months of deployment, and the semi-synthetic sirolimus analogue Biolimus A9™, which has antiproliferative effects and has been proven superior over first-generation sirolimus-eluting DES. The AXXESS™ stent is CE marked and has UK approval. It is currently available in 3.0 mm (expandable to 3.75 mm) and 3.5 mm (expandable to 4.25 mm) diameters, and in two lengths (11 and 14 mm). A 4.0 x 9 mm device has been developed and used in a limited number of cases in the UK, mainly in the left main stem (LMS), where a bifurcation angle of 120° can be spanned. However, this iteration of the device it is not currently available.

**Figure 1: Histopathological Distribution of Atheroma at the Carina**

Panel A shows a histopathological section of a large calibre coronary bifurcation, illustrating the lack of atheroma at the carina - indicated by area G. Histograms in panel C describe plaque thickness and necrotic core thickness throughout the bifurcation, with the histogram bars referring to the area of the bifurcation illustrated in Panel B (A,B,C etc). This systematic evaluation describes the atheroma distribution across this area. Reproduced from Nakazawa et al with permission from the American College of Cardiology.

**Figure 2**
sheath contains more than half the stent length (identified by the deployment marker on the delivery catheter), further adjustment of the stent position is possible. It is often helpful to confirm accurate carina spanning by gently advancing the device forward while the cover sheath remains in this position, as adjustments can still be made at this point. This should be visualised in two orthogonal radiographic projections to ensure separation of the three markers into the MV and SB. It should be stressed, however, that the device cannot be recaptured and the cover sheath cannot be re-advanced over the expanded stent.

The final positioning manoeuvre occurs with gentle forward pressure applied with the device spanning the carina, and full retraction of the cover sheath using the actuator. Ideally, the device should be placed 2–3 mm distal to the carina to maximise distal vessel stent coverage (Figure 3).

Following deployment of the AXxESS stent, the jailed wire can then be withdrawn and reintroduced if needed, with easy access maintained into the other branch. Further stents can then be advanced if required and deployed in the distal MV or SB. If a distal stent is required, then the operator should aim for a minimal overlap of 1–2 mm between the AXxESS and any further stents. Similarly, significant proximal disease to the edge of the AXxESS stent in the MV can be treated with overlapping DES as appropriate. In the authors’ experience, Biomatrix devices have been used, conventionally, as they carry the non-compliant (NC) balloon is placed within the distal marker of the AXxESS stent, often a final hugging balloon dilatation with the SB is performed. An appropriate non-compliant (NC) balloon is placed within distal marker of the AXxESS stent in the SB against an NC balloon in the MV. If both MV and SB are effective in the majority of PCI operators; however, the simple steps outlined above should be followed to minimise this risk of complications. It is advisable to undergo a short period of proctoring before attempting implantation solo as the delivery of the device differs from a conventional balloon expandable stent, as is detailed above. Adjunctive use of intracoronary imaging permits clear definition of the bifurcation anatomy and suitability for a dedicated device, and also facilitates appropriate lesion preparation that permits optimisation of the final stent result. It is recommended in the early learning curve of a new operator that such imaging is performed. While AXxESS can be used safely in the left main stem, it is not advisable for AXxESS implantation to be attempted in this circumstance until a number of successful AXxESS deployments have been undertaken in non-left main bifurcation lesions.

There are a small number of potential problems that may be encountered during implant that can be mitigated by careful technique. These are outlined below, along with simple solutions that are effective in the majority of cases.

**Problem 1: Failed to deliver AXxESS**

Delivery device failure should be considered a possibility when planning the case. However, with a careful strategy and appropriate equipment this risk is minimised. As detailed above, it is important to select a supportive guiding catheter along with good distal supportive guide-wires at the outset. Lesion preparation is crucial, with ideally 1.1 balloon sizing and predilatation with NC, with or without cutting balloons as appropriate. Failure to prepare the vessel adequately is the most common reason for device delivery failure and can easily be overcome with more debulking. It is safe to remove the device if the cover sheath remains fully closed but caution should be taken once the distal stent is exposed. If this circumstance is encountered, it is
Bifurcations

The central flow chart describes the factors that should be considered during stent implantation, along with the problems that may be encountered. Problem 1 – unable to pass AXXESS stent; solution – further lesion preparation. Problem 2 – AXXESS deployed too proximally; solution – post dilatation and introduction of second AXXESS device deployed distal to first. Problem 3 – AXXESS deployed too distally; solution – treat AXXESS as provisional main vessel stent with kissing balloon inflation/completion of culotte as appropriate. Problem 4 – distal stent deployed in too distal position, missing overlap; solution – deploy further stent across gap to ensure ostial lesion coverage.

Figure 5: Optical Frequency Domain Imaging of Axxess at implant and 6 Months Follow Up

Figure 4: Tips and Tricks for Successful AXXESS Delivery

Problem 3: AXXESS Delivered too Distally
If the device is delivered too distally, it will be unable to expand fully and span across the carina. This may be corrected if the device is only just distal of the carina with a kissing balloon inflation that may flare the struts across the carina. If this is ineffective, or the device is positioned in such a way that this is clearly not possible, then it can be used safely and effectively as a provisional MV stent. The SB may be accessed through the device and the procedure completed using a culotte technique with FKBD if SB stenting is required or a provisional approach can be adopted.

Problem 4: Distal Stent Overlap
If a stent is required distally to the AXXESS device, then care should be taken with the positioning of the proximal stent edge to ensure overlap. If there is a suspicion that a gap remains between the two devices, then this should be confirmed using intracoronary imaging (intravascular ultrasound [IVUS] or optical coherence tomography [OCT]) and a further short stent used to cover as appropriate.

The majority of problems with the delivery and positioning of AXXESS can be predicted. By simply considering the factors detailed in Figure 4 when planning the procedure, the risk of a serious complication can be minimised.

Outcomes
There is a growing body of literature that supports the use of the AXXESS system in the treatment of coronary bifurcation lesions. The first-in-man AXXESS PLUS trial reported results at 6 months in 139 patients who underwent implantation across 13 centres, with low rates of TLR (7.5 %) and late-lumen loss (0.09 mm). There was a low rate of periprocedural complications (MACE rate 5% (n=7), non-Q-wave MI 4.3% (n=6)), with a late-stent thrombosis rate of 2.1 % (three patients, two of who associated with premature cessation of antiplatelet therapy).

This trial has been followed with the prospective DIVERGE study, that assessed 302 patients across 14 centres in Europe, Australia and New Zealand. The cumulative MACE rate at 9 months was 7.7 % (0.7 % death, 3.3 % non Q-wave MI, 1.0 % Q-wave MI and 4.3 % TLR). This is comparable to the equivalent MV stent (Biomatrix) with the 9-month MACE rate in the Biolimus arm of the LEADERS trial being reported as 9.2 %. Importantly, 64 % of patients treated with AXXESS had additional DES (in both MV or SB) and all DES used were first-generation sirolimus-eluting devices. Stent thrombosis was observed in 1.0 % of patients (0.7 % subacute and 0.3 % late), the overwhelming majority of which occurred within the additional DES rather than the AXXESS device. The overall restenosis rate was 6.4 %. Both the AXXESS PLUS and the DIVERGE study have now reported 5 years results – pooled data represent a patient population of 432 patients. The overall MACE rate was reported at 21.3 % (6.5 % death, 8.6 % MI and 12.4 % ischaemia-driven TLR). This is comparable to the MACE rate of 22.8 % observed in the Biolimus arm of the LEADERS study at 5 years, and to the 5-year MACE rate of at 18.3 % in the MV-only arm in the NORDIC bifurcation trial.

Importantly, among the DIVERGE cohort, 36 % of patients with true bifurcation lesions were treated using a single device only, or with a single additional stent in either MV or SB. This is an equivalent approach to a provisional technique, but maintaining SB access, and leaving the carina free from metallic scaffold. Indeed, the
MACE rate in this sub-group was 18%, again comparable to the provisional MV-only arm of the NORDIC trial. Importantly, this was not significantly different to the MV-plus-SB group using AXcess (MACE rate of 23.3%). Whereas, when a two-stent technique was employed within the NORDIC trial the overall MACE rate was 28.2%, which was significantly different to the MV-only stent arm. The overall MACE rate for the MV arm of nordic bifurcation at 5 years was 18.3%.

The DIVERGE and AXcess PLUS trial both had stringent inclusion criteria, with the treated lesion dimensions restricted to just 10 mm extension into the MV proximal to the bifurcation, and 15 mm into either branch (MV and SB). They excluded lesions with angiographically apparent heavy calcification. It may be called that this does not reflect ‘real-world’ practice, but observational data are available to support the use of AXcess in more complex lesion subsets. In our data series from over 100 implants across four UK centres, the device has been successfully deployed in a variety of situations, including heavily calcified vessels that require rotablation, chronic total occlusions and in vessels that contain multiple bifurcations and where angles exceed 70°. The overall complication rate was low, with a single access site-related retroperitoneal bleed, and a single coronary perforation following post dilatation of the MV AXcess stent, representing a 2% complication rate, similar to that in other published series.

The single randomised trial in the literature, the COBRA study, compares the use of the AXcess system alongside Biomatrix stents with a two-stent culotte strategy using Xience Pro stents (Abbott Vascular, Illinois, USA) in a cohort of 40 patients with true bifurcation lesions. The trial was conducted at two European centres, with FKB inflations being performed in all cases. All patients were restudied at 9 months with quantitative coronary angiography (QCA) and OCT. There were no significant differences observed in the OCT primary endpoint – the proportion of uncovered struts per bifurcation segment – with a trend towards a higher proportion of uncovered struts in the AXcess group. However, both the mean stent area and mean lumen area in the proximal MV were significantly greater when the AXcess system had been used. This was consistent with the QCA findings, with in-stent late-lumen loss significantly lower within the AXcess arm at both the bifurcation core and within the segment of disease covered with the AXcess stent (0.04 mm versus 0.39 mm; p=0.002) There was no significant differences in clinical outcomes reported at 1 year, as could be expected from this small cohort. This finding is consistent with the results of the IVUS subgroup of the DIVERGE study that demonstrated a 26% increase in luminal volume at 6 months. This is likely to be a consequence of the self-expanding nature of the AXcess device, maximising luminal gain from a PCI bifurcation procedure. The OCT findings at 6 months are illustrated in Figure 5.

There remains a lack of large-scale prospective randomised data evaluating the use of the AXcess system. Despite this, cohort reports and the prospective data presented above have indicated that the system is safe, effective and with rates of adverse outcomes that are comparable to that observed in large-scale randomised biolimus-eluting stent trials.

**Conclusion**

The AXcess system presents a novel solution for the treatment of de novo coronary bifurcation lesions. It has been proven to be associated with low rates of MACE and stent thrombosis, and has a number of theoretical benefits over conventional two-stent strategies. Prospective data support its use in complex coronary bifurcations, however, its use has yet to be studied in a large-scale randomised controlled trial.

---

4. Louvard Y, Thomas M, Dzavik V, et al. AXcess™ Stent: Delivery Indications and Outcomes